Pharma Focus Asia

PixarBio Corporation Announces Signed Agreement with Lubrizol’s Division

Monday, December 18, 2017

PixarBio Corporation developers of NeuroRelease™ NR14, a 14-day post-surgical pain treatment, announces an agreement between Particle Sciences (PSI), a Lubrizol Corporation Company, to cGMP manufacture PixarBio’s NR14 product for clinical trials. In 2018, PixarBio will be able to apply to the US FDA for fast track approval through the CDER Breakthrough Therapy designation.

“Although the agreement covers our 14 day treatment, we also have a 7 and 3 day product in our pipeline that are not part of this agreement. We worked for over 3 years with PSI to put this agreement in place and look forward to a long term collaboration. I am confident that with the FDA’s fast track approval we can receive FDA clearance to market NR14 in late 2019,” said CEO Frank Reynolds.

The NeuroRelease™ Platform: Non-Addictive and Non-opiate Treatment of Pain
NeuroRelease™ is a morphine replacement, and non-addictive pain platform for post-surgical pain. First product FDA approval for the platform will be for a 14-day post-surgical pain treatment and it is expected in late 2019. The platform can be formulated for acute and chronic pain treatments.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024